

ABSTRACT OF THE DISCLOSURE

- 5 Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors,
and methods of using these compositions for inhibiting the replication of the hepatitis
C virus (HCV) and for the treatment of an HCV infection. These compositions are
lipid based systems and comprise the hepatitis C viral protease inhibitor together with
at least one pharmaceutically acceptable amine, at least one pharmaceutically
10 acceptable base, at least one pharmaceutically acceptable oil and optionally one or
more additional ingredients.